Organization (Academic)
Universität des Saarlandes
ClinicalTrials.gov lists Universität des Saarlandes as lead sponsor of 68 trials. It has 46 active development programs and 21 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
Logo Hiedano, via Wikimedia Commons, CC BY-SA 4.0. Shown to identify the organization; it may be a registered trademark.
This page covers Universität des Saarlandes: 68 lead-sponsored trials and 1 legal-entity registration.
Disease areas (85)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Heart Failure | 5 |
| Parkinson Disease | 4 |
| COVID-19 | 3 |
| Coronary Artery Disease | 3 |
| Coronary Disease | 3 |
Showing 5 of 85 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2024 | 2 |
| 2023 | 10 |
| 2022 | 2 |
| 2021 | 5 |
| 2020 | 5 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 3 |
Showing 10 of 22 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (46)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PEMBROLIZUMAB | Head and Neck Neoplasms | Phase 3 | 2 |
| PEMBROLIZUMAB | Carcinoma, Squamous Cell | Phase 3 | 2 |
| PEMBROLIZUMAB | Squamous Cell Carcinoma of Head and Neck | Phase 3 | 2 |
| R-miniCHOP | Lymphoma, B-Cell | Phase 3 | 1 |
| R-miniCHOP | Lymphoma, Non-Hodgkin | Phase 3 | 1 |
Showing 5 of 46 active programs.
Approved assets (21)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ferric Carboxymaltose | 1 |
| Influenza Vaccination | 1 |
| Iron Isomaltoside 1000 | 1 |
| PEMBROLIZUMAB | 2 |
| CISPLATIN | 1 |
Showing 5 of 21 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 60% hit target (n=15) | 43% on time (n=14) |
Journals published in (100)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| European journal of nuclear medicine and molecular imaging | 5 |
| Journal of neurology, neurosurgery, and psychiatry | 5 |
| Journal of the American College of Cardiology | 5 |
| American journal of epidemiology | 4 |
| Clinical chemistry and laboratory medicine | 3 |
Showing 5 of 100 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 27 | 6 | 2025-02-18 |
Organization relationships (29)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Leipzig University | Co sponsors trial with | 2 |
| University Hospital Schleswig-Holstein | Co sponsors trial with | 1 |
| Masaryk University | Co sponsors trial with | 1 |
| Technical University of Munich | Co sponsors trial with | 1 |
| Eötvös Loránd University | Co sponsors trial with | 1 |
Showing 5 of 29 relationships.
Latest dated events (108)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 108 events.
Biomarker capability evidence (76)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCD1 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| BCHE | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 76 evidence rows.
Biomarkers this organization publishes on (407)
Shown in this order: most publications first.
Showing 5 of 407 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.